CBD Gummies Recall: 61,000+ Products Pulled for Safety Alerts

More Than 61,000 CBD Gummies Recalled for Cross-Contamination

If it feels like cannabidiol products, better known as CBD, have popped up everywhere over the last decade, it’s because they really have — in the form of gummies, tinctures, topical oils, and other goods promising to relax the body, relieve pain, and enable sleep. Now, a total of 61,460 CBD gummies have been recalled nationwide in the U.S. and internationally throughout Australia, Germany, the United Kingdom, Malaysia, and New Zealand. The U.S. Food and Drug Administration (FDA) has named the popular Colorado-based company Extract Labs, Inc. as the recalling firm.

Reason for Recall and Potential Risks

A roundup of FDA Warning Letters for Cannabis-Derived Products suggests that many regulatory concerns involving CBD products are triggered by the companies making unsubstantiated medical claims or including unapproved ingredients in their formulas. The reason for the FDA’s current gummies recall may surprise some: there was a “potential peanut protein cross-contact,” posing a possible risk to those with peanut allergies.

On September 22, the recall was updated to reflect a Class II designation, suggesting that exposure to the product could cause temporary or reversible harm. However, in addition to more common symptoms such as hives and shortness of breath, severe peanut allergies can lead to anaphylaxis, which can be life-threatening.

Peanut Allergy Statistics and Safety Concerns

An estimated 6.1 million Americans have a peanut allergy, and nearly 1.5 million are children. While accidental peanut exposure can be cause for serious concern, CBD gummies can pose another health risk if children accidentally consume them. Although CBD is less likely to cause symptoms of a “high,” the safety and effectiveness of CBD for children is still being researched.

Affected Products and Details

• 2,180 Sugar-free Mixed Berry Gummies (10mg CBD and 10mg D9 THC per gummy); Lot Number/Batch ID: 25E5082907A; Expiration: 07/2027 (printed on the bottom of the bottle)
• 19,720 Elderberry 20mg Gummies (20mg CBD and 20mg D9 THC per gummy); Lot Number: 25JD072107A; Expiration: 07/2027 (printed on bulk bag identifier adhesive)
• 19,810 Blue Razz 20mg Gummies (20mg CBD and 20mg D9 THC per gummy); Lot Number: 25JD082307A; Expiration: 07/2027 (printed on bulk bag identifier adhesive)
• 19,750 Mai Tai 20mg Gummies (20mg CBD and 20mg D9 THC per gummy); Lot Number: 25JD042507A; Expiration: 07/2027 (printed on bulk bag identifier adhesive)

Additional details, including any available UPC, dosage, or packaging information is available at the above FDA recall link.

Consumer Caution and FDA Regulation

Despite its popularity, many people still have reservations about CBD use. Consumers should exercise caution since many over-the-counter CBD products are largely unregulated by the FDA. The health authority warns of the risks associated with CBD use, especially concerning children, people who are pregnant or breastfeeding, and individuals taking other medications.

For more daily wellness updates, subscribe to The Healthy newsletter and follow The Healthy on Facebook and Instagram.

• 157,000 More Pounds of Frozen Seafood Recalled from Major Grocers in 31 States in Ongoing Food Safety Event
• Hepatitis B Drug Recalled for Safety Concerns in a Nearly 9,000-Bottle Quantity
• An Ongoing Frozen Veggies Recall Has Been Upgraded to the Nation’s Highest Risk Level
• More Than 165,000 Bottles of a Trusted Pain & Mood Drug Were Recalled Nationwide